External Ventricular Drain Management in Hydrocephalus

Clinical Indications and Management

• The American Heart Association recommends urgent CSF diversion through EVD in patients with acute symptomatic hydrocephalus to improve neurological outcome, which represents a Class 1 recommendation with strong evidence 1, 2
• EVD placement is indicated in patients with aneurysmal subarachnoid hemorrhage when hydrocephalus develops, which occurs in a significant proportion of these patients 1, 2
• The American College of Cardiology suggests that EVD is a Class 1 indication for intracerebral hemorrhage with hydrocephalus when hydrocephalus causes decreased level of consciousness, as it reduces mortality 3
• For patients with intraventricular hemorrhage, EVD placement is reasonable when accompanied by reduced consciousness (GCS ≤8) 3
• The European Stroke Organisation recommends that EVD placement should be considered in intracerebral hemorrhage patients with a Glasgow Coma Scale score ≤8, clinical evidence of transtentorial herniation, or hydrocephalus with decreased level of consciousness 3

Infection Prevention and EVD Management Protocols

• Implementation and adherence to an EVD bundled protocol that addresses insertion, management, education, and monitoring are recommended to reduce complication and infection rates, with infection risk ranging from <1% to 45% depending on management practices 1, 2
• Key protocol elements include aseptic technique, proper skin preparation, catheter selection, type and frequency of dressing changes, CSF sampling frequency and technique, flushing protocols, healthcare professional training, tracking catheter days, and monitoring infection rates 1, 2, 4

Transition to Permanent CSF Diversion

• For patients with chronic symptomatic hydrocephalus following acute treatment, permanent CSF diversion is recommended to improve neurological outcome, with chronic shunt-dependent hydrocephalus occurring in 8.9% to 48% of patients with subarachnoid hemorrhage 1, 2, 4, 5
• Predictors of shunt dependency include poor admission neurological grade, increased age, acute hydrocephalus requiring EVD, high Fisher grades, presence of intraventricular hemorrhage, and prolonged period of EVD use 1, 4, 5

Enhanced EVD Therapy

• For patients with GCS >3 and primary intraventricular hemorrhage or IVH extension from supratentorial ICH <30 mL requiring EVD, adding intraventricular thrombolytic to EVD is safe and reasonable compared with EVD alone to reduce mortality 3
• The European Stroke Organisation cannot make strong recommendations about routine use of EVD with intrathecal thrombolysis for spontaneous intracerebral hemorrhage without strong evidence from RCTs 6, 7

Management of Worsening Hydrocephalus with EVD in Place

Immediate Assessment and Troubleshooting

• When hydrocephalus worsens despite an EVD in place, immediately verify EVD patency and positioning, optimize drainage parameters, and consider adding intraventricular thrombolytic therapy if intraventricular hemorrhage is present 8, 9, 10
• Assess for catheter obstruction by blood clot or debris, particularly in patients with intraventricular hemorrhage 8, 9
• Monitor for declining Glasgow Coma Scale score, new pupillary changes, or signs of transtentorial herniation 10
• Obtain urgent neuroimaging to assess ventricular size progression and rule out new hemorrhage or mass effect 8, 9

Therapeutic Interventions

• For patients with intraventricular hemorrhage and GCS >3, adding alteplase or urokinase to EVD irrigation significantly reduces mortality compared to EVD with saline alone 8, 9, 10
• The American Heart Association/American Stroke Association gives this a Class 2a recommendation based on the CLEAR III trial and multiple meta-analyses 8, 9
• Thrombolytic irrigation hastens clot removal and improves CSF circulation 9, 10
• This approach is safe with no increased risk of symptomatic hemorrhage, and actually shows lower rates of ventriculitis 8, 9

Addressing Underlying Causes

• New hemorrhage or rebleeding can obstruct CSF pathways 11
• Cerebral vasospasm in SAH patients may contribute to clinical worsening independent of hydrocephalus 11
• In aneurysmal SAH, acute hydrocephalus occurs in 15-87% of patients and may evolve over the first days to weeks 11

Transition to Definitive Management

• Chronic symptomatic hydrocephalus should be treated with permanent CSF diversion (ventriculoperitoneal shunt) per AHA/ASA Class I recommendation 11
• Prolonged EVD weaning (>24 hours) does not reduce shunt dependency and should not be routinely performed 11

Common Pitfalls to Avoid

• Do not delay imaging when clinical worsening occurs—urgent CT is essential to guide management 8, 9
• Do not continue ineffective EVD management—if standard measures fail, escalate to thrombolytic therapy (if IVH present) or consider additional drainage 8, 9, 10
• In aneurysmal SAH, do not attribute all neurological worsening to hydrocephalus alone—consider vasospasm, rebleeding, and seizures as concurrent issues 11

Evidence‑Based Recommendations for the Management of Hydrocephalus

Acute Hydrocephalus Management

• Urgent cerebrospinal fluid (CSF) diversion with an external ventricular drain (EVD) or lumbar drainage is required for all patients with acute symptomatic hydrocephalus to prevent neurological deterioration and improve outcomes (Class I recommendation) 12.
• Lumbar drainage may be used as an alternative to EVD when ventricular access is difficult or contraindicated, particularly in communicating hydrocephalus (Class I) 12.

Standardized EVD Care

• Implementation of a bundled EVD protocol—including aseptic insertion, antibiotic‑impregnated catheters, standardized dressing changes, defined CSF sampling, staff training, and systematic tracking of catheter days—reduces infection rates from as high as 45 % to < 1 % (Class I) 12.

Chronic Hydrocephalus Management

• Placement of a permanent ventriculoperitoneal shunt for all patients with chronic symptomatic hydrocephalus improves neurological outcomes (Class I recommendation) [12][13].
• Shunt‑dependent hydrocephalus develops in 8.9 %–48 % of patients after subarachnoid hemorrhage (observational data) [12][13].
• Predictors of shunt dependency include poor admission neurological grade, older age, acute hydrocephalus requiring an EVD, high Fisher grade, presence of intraventricular hemorrhage, re‑bleeding, and prolonged EVD duration (observational data) 12.
• Prolonged EVD weaning protocols (> 24 h) do not reduce the need for permanent shunting and only delay definitive treatment (Class III recommendation) 13.

Hydrocephalus in Premature Infants (Post‑hemorrhagic)

• Temporary CSF diversion using ventricular access devices (VADs), ventriculosubgaleal (VSG) shunts, or EVDs is recommended based on clinical judgment (Level II evidence) [14][15].
• VSG shunts lower the requirement for daily CSF aspiration compared with VADs (Level II) [14][15].
• VADs are preferred over EVDs because they are associated with reduced morbidity and mortality (Level II) [14][15].
• Serial lumbar punctures should not be used routinely to prevent shunt placement or hydrocephalus progression (Level I, high certainty) [14][15].
• Acetazolamide and furosemide should not be used; they do not decrease permanent shunt need and increase mortality and neurological morbidity at one year (Level I) [14][16]15.
• Intraventricular thrombolytics (tPA, urokinase, streptokinase) should not be used; they do not reduce shunt placement and may increase secondary intraventricular hemorrhage (Level I) [14][15].

Subarachnoid Hemorrhage‑Associated Hydrocephalus

• Acute hydrocephalus occurs in 15 %–87 % of patients with aneurysmal subarachnoid hemorrhage (observational data) [17][13].
• CSF diversion (EVD or lumbar drainage) is indicated for acute symptomatic hydrocephalus in this setting (Class I, Level B evidence) [17][13].
• The risk of aneurysm re‑bleeding associated with EVD placement remains controversial, with conflicting retrospective data (expert opinion) [17][13].
• Routine fenestration of the lamina terminalis does not reduce the incidence of shunt‑dependent hydrocephalus (Class III recommendation) [17][12]13.